12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

More documents

Recommendations

Info

allogen transplantation kan anvendes ved alder over 55 år. Primær resistent ALL (induction failure) eller ALL i relaps Der er ikke indikation for allogen HCT. Referencer vedrørende HCT af ALL hos voksne Risikofaktorer Hoelzer, D., Thiel, E., Loffler, H., Buchner, T., Ganser, A. et al (1988). Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood, 71, 123-131. Gleissner B, Goekbuget N, Rieder H et al (2005). CD10- pre-B acute lymphoblastic leukaemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood, 106, 4054-4056. Czuczman M, Dodge R, Carleton C, Stewart RS et al (1999). Value of immunephenotype in intensively treated adult acute lymphoblastic leukaemia: Cancer and Leukemia Group B study 8364.Blood, 93, 3931-3939. Ferrando A, Neuberg DS, Dodge RK, Paiette E et al (2004). Prognostic importance of TLX1 (HOX11) oncogen expression in adults with T-cell acute lymphoblasic leukaemia. Lancet, 363, 535-536. Faderl, S., Kantarjian, H.M., Talpaz, M., and Estrov, Z (1998). Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood , 91, 3995-4019. Wetzler M, Dodge R, Mrózek K, Carroll A et al (1999). Prospective kareotype analysis in adult ac ute lymphoblastic leukaemia: The Cancer and Leukemia Group B experience. Blood, 93,3983-3993. Charrin C, Thomas X, Ffrench M, Le Q-H et al (2004). A report from the LALA-94 and LALA-SA groups on hypodiploidi with 30-39 chromosomes and near-triploidi: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukaemia (ALL). Blood,104, 2444-2451. Harrison C, Moorman A, Broadfield Z, Cheung K et al (2004). Three distinct subgroups of hypodiploidi in acyte lymphoblastic leukaemia. Brit J Haematol , 125, 552-559. Lazarus H, Richards S, Chora R et al (2006): Central nervous system involvement in adult acute lymphoblastic leukaemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E 2993. Blood, 108, 465- 472. Bruggemann M, Raff T, Flohr T et al (2006): Clinical significans of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukaemia. Blood, 107, 1116-1123. Moorman AV, Harrison CJ, Buck GAN et al (2007): Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia(ALL): analysis of cytogenetic data from patients treated on the Medican Research Council (MRC) UKALLXII/Eastern Cooporative Oncology Group (ECOG) 2993 trial. Blood, 109, 3189-3197. Thomas DA, O’Brien S, Jorgensen JL, et al (2008): Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukaemia. Blood, prepublished online 14 Aug 2008. 18
Kemoterapi Hoelzer, D.F (1993). Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol.Oncol.Clin.North Am., 7, 139-160. Larson, R.A., Dodge, R.K., Burns, C.P., Lee, E.J. et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood , 85, 2025-2037. Copelan E, McGuire E.(Review) (1995). The biology and treatment of acute lymphoblastic leukaemia in adults. Blood, 85, 1151-1168. Laport, G.F. and Larson, R.A (1997). Treatment of adult acute lymphoblastic leukemia. Semin.Oncol., 24, 70-82. Rowe J, Buck G, Burnett A et al (2005). Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 106, 3760- 3767. Autolog HCT Abdallah A, Egerer G, Goldschmidt H, Wannenmacher M et al (2001) Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol ,112, 1012-1015. Attal, M., Blaise, D., Marit, G., Payen, C. et al (1995). Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood, 86,1619-1628. Fiere, D., Lepage, E., Sebban, C., Boucheix, C et al (1993). Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J.Clin.Oncol., 11, 1990-2001. Gorin NC (2002). Autologous stem cell transplantation in acute lymphocytic lukemia. Stem Cells, 20 (1): 3-10. Weisdorf D, Bishop M, Dharan B, Bolwell B et al (2002). Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukaemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant, 8, 213-220. Goldstone AH, Richards SM, Lazarus HM, et al (2008). In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL trial (MRC UKALL XII/ECOG E2993. Blood, 111. 1827-1833. Allogen HCT 19
Page 1 and 2: Rekommandationer for knoglemarvstra
Page 3 and 4: Vævstyper og terminologi Ved valg
Page 5 and 6: 3.valg: 9/10 allel forligelig ubesl
Page 7 and 8: Petersdorf EW et al: Major-histocom
Page 9 and 10: Sygdomsspecifikke overvejelser & kr
Page 11 and 12: Non myeloablativ stamcelletransplan
Page 13 and 14: Akutte Leukæmier ALL hos voksne AL
Page 15 and 16: En metaanalyse af 7 studier, hvor a
Page 17: Højrisikofaktorer • Fænotype: N
Page 21 and 22: unrelated transplant in first compl
Page 23 and 24: ALL hos børn 5% blaster i knoglema
Page 25 and 26: i det nordamerikanske register, af
Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
Page 29 and 30: Autolog KMT Litteraturen på områd
Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
Page 33 and 34: myelogenous leukemia in first compl
Page 35 and 36: AML hos børn
Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
Page 41 and 42: *) Specielt i denne gruppe gælder
Page 43 and 44: Kantarjian H, O'Brien S, Cortes J,
Page 45 and 46: Scott BL, Sandmaier BM, Storer B, M
Page 47 and 48: tiltagende. Patienter med RC og hø
Page 49 and 50: Donor leukocyte infusion after hema
Page 51 and 52: � Konstitutionelle symptomer, for
Page 53 and 54: Responskriterier ved CML Responstyp
Page 55 and 56: patienter, som statistisk set vil h
Page 57 and 58: Mauro,M.J. (2006) Defining and mana
Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
Page 61 and 62: Der er ingen data, der indicerer at
Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
Page 67 and 68: Der er ikke indikation for autolog
Page 69 and 70:
sequential chemotherapy in poor-ris
Page 71 and 72:
af immunosuppressiv beh. og DLI og
Page 73 and 74:
following high-dose sequential chem
Page 75 and 76:
Marginal Zone Lymfom Senest revider
Page 77 and 78:
Rezvani AR, Storer B, Maris M et al
Page 79 and 80:
eskriver også sammenhæng mellem i
Page 81 and 82:
HCT ved refraktær sygdom (Verdonck
Page 83 and 84:
transplantation for lymphoprolifera
Page 85 and 86:
Perifere T-Celle Lymfomer Senest re
Page 87 and 88:
Referencer: Evens AM, Gartenhaus RB
Page 89 and 90:
Hodgkin Lymfom (HL) Senest revidere
Page 91 and 92:
Patienter med progressiv sygdom ell
Page 93 and 94:
Transplant, 12,172-183. Anderlini,P
Page 95 and 96:
Allogen KMT 1. HLA-identisk søsken
Page 97 and 98:
Referencer Definition Bacigalupo A,
Page 99 and 100:
Paroxysmal Nocturn Haemoglobinuri,
Page 101 and 102:
Autolog transplantation Myelomatose
Page 103 and 104:
Cavo M, Tosi P, Zagmani E, Cellini
Page 105 and 106:
Myelofibrose Idiopatisk myelofibros
Page 107 and 108:
Introduktion Retransplantation af b
Page 109 and 110:
Den samlede konklusion kunne være,
Page 111 and 112:
Thalassæmier Senest revideret nove
Page 113 and 114:
thalassæmifri overlevelse på 66%
Page 115 and 116:
Kronisk granulomatøs sygdom Senest
show all

12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Create successful ePaper yourself

Delete template?

Save as template?